scholarly journals Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Yurina Harada ◽  
Makoto Kubo ◽  
Masaya Kai ◽  
Mai Yamada ◽  
Karen Zaguirre ◽  
...  
Keyword(s):  
Genital Tract ◽  
Abdominal Cavity ◽  
Female Genital Tract ◽  
Serous Carcinoma ◽  
High Grade ◽  
Peritoneal Cancer ◽  
Cancer Tumor ◽  
Stage Ivb ◽  
The Right ◽  
Female Genital

Abstract Background Metastatic tumors to the breast reportedly account for 0.5% to 2.0% of all malignant breast diseases. Such metastatic tumors must be differentiated from primary breast cancer. Additionally, few reports have described metastases of gynecological cancers to the breast. We herein report two cases of metastasis of pelvic high-grade serous adenocarcinoma to the breast. Case presentation The first patient was a 57-year-old woman with a transverse colon obstruction. Colostomy was performed, but the cause of the obstruction was unknown. We found scattered white nodules disseminated throughout the abdominal cavity and intestinal surface. Follow-up contrast-enhanced computed tomography (CT) showed an enhanced nodule outside the right mammary gland. Core needle biopsy (CNB) of the right breast mass was conducted, and immunohistochemical staining of the mass suggested a high-grade serous carcinoma of female genital tract origin. We diagnosed the patient’s condition as breast and lymph node metastasis of a high-grade serous carcinoma of the female genital tract. After chemotherapy for stage IVB peritoneal cancer, tumor reduction surgery was performed. The second patient was a 71-year-old woman with a medical history of low anterior resection for rectal cancer at age 49, partial right thyroidectomy for follicular thyroid cancer at age 53, and left lower lung metastasis at age 57. Periodic follow-up CT showed peritoneal dissemination, cancerous peritonitis, and pericardial effusion, and the patient was considered to have a cancer of unknown primary origin. Contrast-enhanced CT showed an enhanced nodule in the left mammary gland with many enhanced nodules and peritoneal thickening in the abdominal cavity. CNB of the left breast mass was conducted, and immunohistochemical staining of the mass suggested a high-grade serous carcinoma of female genital tract origin. After chemotherapy for stage IVB peritoneal cancer, tumor reduction surgery was performed. Conclusions We experienced two rare cases of intramammary metastasis of high-grade serous carcinoma of female genital tract origin. CNB was useful for confirming the histological diagnosis of these cancers that had originated from other organs. A correct diagnosis of such breast tumors is important to ensure quick and appropriate treatment.

scholarly journals THE SELECTIVE LOCALIZATION OF MURINE PLEUROPNEUMONIA-LIKE ORGANISMS IN THE FEMALE GENITAL TRACT ON INTRAPERITONEAL INJECTION IN MICE

1954 ◽  
Vol 100 (3) ◽  
pp. 311-320 ◽  
Author(s):  
John B. Nelson
Keyword(s):  
Respiratory Tract ◽  
Otitis Media ◽  
Genital Tract ◽  
Intraperitoneal Injection ◽  
Abdominal Cavity ◽  
Female Genital Tract ◽  
Male Mice ◽  
Selective Localization ◽  
Female Genital

Acute oophoritis and salpingitis were commonly observed in weanling mice injected intraperitoneally with murine pleuropneumonia-like organisms of the catarrhal type (4 strains). Organisms of the injected strain were regularly recovered in cultures from the ovary or uterus during the 3rd to the 5th week but not after the 12th week. They were also obtained from the vagina through the 5th week and with varying results, depending on the strain, from the heart's blood through the 1st week. PPLO injected into the vagina survived for some weeks but did not migrate inwardly nor were they transmitted outwardly to exposed mice. In male mice peritoneal abscesses were sometimes present but the genital organs were normal and free from PPLO. Otitis media, with positive exudate cultures, occurred more often in females and varied in rate with the strain of PPLO. PPLO of the conjunctival type failed to survive in the abdominal cavity of mice and produced no reaction in either the genital or the respiratory tract.

scholarly journals Inflammatory Myofibroblastic Tumor in Female Genital Tract

2018 ◽  
Vol 143 (1) ◽  
pp. 122-129 ◽  
Author(s):  
Pratibha Sharma Shukla ◽  
Khushbakhat Mittal
Keyword(s):  
Smooth Muscle ◽  
Genital Tract ◽  
Inflammatory Myofibroblastic Tumor ◽  
Abdominal Cavity ◽  
Female Genital Tract ◽  
High Recurrence Rate ◽  
Positive Staining ◽  
Molecular Features ◽  
Mesenchymal Neoplasm ◽  
Female Genital

Context.— Inflammatory myofibroblastic tumor is a mesenchymal neoplasm of low malignant potential. It was first described in lung, but is known to occur in many extrapulmonary sites including female genital organs, most commonly the uterus. It has a high recurrence rate and a low risk for metastasis. A more recently described aggressive variant, epithelioid myofibroblastic sarcoma with a predilection for the abdominal cavity of males, has also been recently reported to occur in the ovary. This tumor is composed of spindled and epithelioid myofibroblasts in a variably myxoid stroma and commonly shows a fascicular growth pattern with positive staining for desmin, smooth muscle actin, and CD10, which may mimic a smooth muscle or endometrial stromal neoplasm. In the female genital tract it has the potential for being misdiagnosed as a leiomyoma, endometrial stromal tumor, or as a myxoid leiomyosarcoma, resulting in undertreatment or overtreatment. It harbors rearrangements in the ALK gene, resulting in abnormal expression of ALK protein. Immunostaining for ALK is a helpful diagnostic tool. Objective.— To provide a brief review of clinical, histologic, immunohistochemical, and molecular features of inflammatory myofibroblastic tumor with emphasis on possible diagnostic pitfalls in the female genital tract. Data Sources.— Review of pertinent literature on inflammatory myofibroblastic tumor occurring in the female genital tract and personal experience of the authors. Conclusions.— Inflammatory myofibroblastic tumor in the female genital tract can mimic other more common benign and malignant tumors like leiomyoma, leiomyosarcoma, and endometrial stromal sarcoma. Familiarity with clinical and histologic features and use of ALK immunostaining can be critical for correct diagnosis.

Uterine serous papillary carcinoma: Histopathologic changes within the female genital tract

2001 ◽  
Vol 11 (4) ◽  
pp. 283-289 ◽  
Author(s):  
L. B. Jordan ◽  
M. Abdul-Kader ◽  
A. Al-Nafussi
Keyword(s):  
Papillary Carcinoma ◽  
Fallopian Tube ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Serous Carcinoma ◽  
Tumor Spread ◽  
Histopathologic Changes ◽  
Serous Papillary Carcinoma ◽  
Female Genital

Abstract.Jordan LB, Abdul-Kader M, Al-Nafussi A. Uterine serous papillary carcinoma: Histopathologic changes within the female genital tract.The histopathologic features of 25 patients with uterine serous papillary carcinoma (USPC) were presented, with particular emphasis on the changes seen in the remaining müllerian epithelium. The mean age at presentation was 68.9 years; 52% of patients were stage III at the time of presentation and 40% died of their disease within 24 months of diagnosis. Histologic assessment revealed: 1) pure serous carcinoma in 56% of patients and mixed differentiation of serous and endometrioid in the remainder; 2) malignant epithelium reminiscent of that of USPC and akin to carcinoma in situ, frequently seen in the remaining endometrium, cervix, and, less commonly, the fallopian tube; 3) residual endometrium that, when identified (11/25 cases), was atrophic in all cases; 4) various types of cervical involvement in 17 cases (68%) ; 5) tumor within the fallopian tube in three cases (12%); and 6) carcinoma with in situ-like features in five cases (20%). In conclusion, it appears that USPC is frequently associated with malignant epithelial changes (as with carcinoma in situ) in the remaining müllerian epithelium. This finding suggests either a field change or, more likely, a transepithelial tumor spread. The latter theory is preferable, because this type of spread is frequently seen on serosal surfaces in cases of serous ovarian carcinoma. Uterine serous papillary carcinoma is, therefore, biologically more akin to its ovarian counterpart.

scholarly journals Tubo-Ovarian Abscess Occurring 16 Years After Supracervical Hysterectomy

2003 ◽  
Vol 11 (3) ◽  
pp. 167-169 ◽  
Author(s):  
Toshimitsu Tohya ◽  
Toshihiro Yoshimura ◽  
Chikashi Onoda
Keyword(s):  
Genital Tract ◽  
Transvaginal Ultrasound ◽  
Female Genital Tract ◽  
Lower Abdominal Pain ◽  
Pathologic Examination ◽  
Supracervical Hysterectomy ◽  
Tender Mass ◽  
The Right ◽  
Ovarian Abscess ◽  
Female Genital

Background:Supracervical hysterectomy is seldom performed and there are few reports of tubo-ovarian abscess (TOA) after supracervical hysterectomy.Case:The case of a 49-year-old woman with a right TOA is reported. This patient had received a supracervical hysterectomy 16 years earlier due to rupture of the uterus. At this admission, she presented with complaints of lower abdominal pain and fever. Bimanual and transvaginal ultrasound examinations demonstrated a tender mass in the right adnexal region. Laparotomy, pathologic examination and microbiologic study confirmed the diagnosis of right TOA.Conclusion:After supracervical hysterectomy, patients may develop endocervicitis, parametritis and/or TOA. This series may be a subtype of ascending infections in the female genital tract.

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract

2014 ◽  
Vol 24 (Supp 3) ◽  
pp. S78-S82 ◽  
Author(s):  
Michael Leonard Friedlander ◽  
Alan Covens ◽  
Rosalind M. Glasspool ◽  
Felix Hilpert ◽  
Gunnar Kristensen ◽  
...  
Keyword(s):  
Genital Tract ◽  
Current Knowledge ◽  
Gynecologic Cancer ◽  
Female Genital Tract ◽  
Endometrial Stromal Sarcoma ◽  
Good Prognosis ◽  
Low Grade ◽  
High Grade ◽  
Stromal Sarcoma ◽  
Female Genital

Mullerian adenosarcomas of the female genital tract are rare malignancies, originally described in the uterus, the most common site of origin, but they may also arise in extrauterine locations. Uterine adenosarcomas make up 5% of uterine sarcomas and tend to occur in postmenopausal women. They are usually low-grade tumors and are characterized by a benign epithelial component with a malignant mesenchymal component, which is typically a low-grade endometrial stromal sarcoma but can also be a high-grade sarcoma. Tumors that exhibit a high-grade sarcomatous overgrowth have a worse outcome. Adenosarcomas have been described as being midway along the spectrum between benign adenofibromas and carcinosarcomas. They generally have a good prognosis with the exception of deeply invasive tumors or those with high-grade sarcomatous overgrowth. Extrauterine adenosarcomas also have a higher risk for recurrence. In view of their rarity, there have not been any clinical trials in mullerian adenosarcomas and relatively little research. This article reviews the current knowledge and provides recommendation for the management of mullerian adenosarcomas.

scholarly journals Immunophenotyping of serous carcinoma of the female genital tract

2008 ◽  
Vol 21 (9) ◽  
pp. 1147-1155 ◽  
Author(s):  
Sharon Nofech-Mozes ◽  
Mahmoud A Khalifa ◽  
Nadia Ismiil ◽  
Reda S Saad ◽  
Wedad M Hanna ◽  
...  
Keyword(s):  
Genital Tract ◽  
Female Genital Tract ◽  
Serous Carcinoma ◽  
Female Genital

scholarly journals Targeted therapy with monoclonal antibodies: Do we observe progress in the management of female genital tract cancers?

2018 ◽  
Vol 72 ◽  
pp. 192-204
Author(s):  
Jacek R. Wilczyński ◽  
Marek Nowak ◽  
Miłosz Wilczyński
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibodies ◽  
Targeted Therapy ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Malignant Ascites ◽  
Peritoneal Cancer ◽  
Ovarian Cancers ◽  
Intraperitoneal Treatment ◽  
Female Genital

Targeted therapy with monoclonal antibodies (moAbs) has become a valuable supplementation for classic chemo- and radiotherapy. The first part of this review presents in a condensed way the characteristics and mechanism of action of moAbs most commonly used and/or tested for therapy of female genital tract malignancies, including: bevacizumab (anti-VEGF-A moAb), cetuximab (anti-EGFR moAb), trastuzumab (anti-ErbB2/HER2 moAb), catumaxomab (anti-EpCAM/anti-CD3 moAb), oregovomab (anti-MUC16 moAb) and farletuzumab (anti-FR-α moAb). The second part of the review discusses the results of the recent clinical trials devoted to the usefulness of moAbs in the management of cervical, endometrial and ovarian cancers. The unquestionable progress in this field has made possible the introduction of bevacizumab for the treatment of advanced ovarian, Fallopian tube or peritoneal cancer, as well as advanced, recurrent or metastatic cervical cancer. Similarly, catumaxomab has been registered for the intraperitoneal treatment of malignant ascites in EpCAM positive ovarian cancer when standard therapy is no longer available.

scholarly journals Rare Malignancies of the Female Genital Tract

2020 ◽  
Vol 15 (1) ◽  
pp. 18-23
Author(s):  
Rijuta Joshi ◽  
Gehanath Baral
Keyword(s):  
Cell Carcinoma ◽  
Granulosa Cell ◽  
Genital Tract ◽  
Single Case ◽  
Female Genital Tract ◽  
Granulosa Cell Tumor ◽  
Cell Tumor ◽  
Serous Carcinoma ◽  
Mixed Germ Cell Tumor ◽  
Female Genital

Aims: To analyze rare female genital tract malignancies. Method: This is retrospective descriptive study as a census of all rare female genital tract malignancies in two years from 2017 to 2019 at Paropakar Maternity and Women’s Hospital in Kathmandu. Data were retrieved from medical record and entered into Microsoft Excel and SPSS 16 window for analysis. Results: There were 156 cases of female genital tract malignancies including 128 common types and 28 rare types. Majority fell under 41- 50 years (n=44; 28.2%) followed by over 60 (n=41; 26.2%) and 51-60 years (n=34; 21.8%). Among ovarian tumors, the rare varieties were adult granulosa cell tumor (n=4), immature teratoma (n=3) and single case each of yolk sac tumor, dysgerminoma, malignant mixed germ cell tumor, carcinoid tumor, juvenile granulosa cell and sertoli cell tumor. There were one case each of carcinosarcoma, serous carcinoma and endometrial stromal carcinoma; two cases each of leiomyosarcoma and choriocarcinoma while there was a single case of placental site trophoblastic tumor. The rare cervical malignancies were small cell (n=2), and clear cell carcinoma (n=1). There were single cases each of basal cell carcinoma of vulva, verrucus carcinoma, fibromyxoid sarcoma of Bartholin’s gland and malignant melanoma of vagina. Conclusion: Rare female genital tract cancers were found mostly from the ovary followed by uterus; 18% of total cancers were rare types. Key words: female, genital tract, rare malignancy

Sign in / Sign up

Export Citation Format

Share Document